Adolescents with Congenital Limb Reduction Deficiency - Perceptions of Treatments During Childhood and their Views of Current Situation and Future

Author(s):  
Lis Sjöberg ◽  
Liselotte Hermansson
2019 ◽  
Vol 48 (6) ◽  
pp. 2010-2017 ◽  
Author(s):  
Jufen Liu ◽  
Zhiwen Li ◽  
Rongwei Ye ◽  
Aiguo Ren ◽  
Jianmeng Liu

Abstract Background Folic acid (FA) supplementation prevents neural tube defects, but there are mixed results for its ability to prevent limb reduction defects. We examined whether a preventive effect of FA supplementation exists for congenital limb reduction defects in a large population in China. Methods Data from a large population-based cohort study in China were used to evaluate the effects of FA supplementation on birth defects. All births at 20 complete gestational weeks, including live births, stillbirths and pregnancy terminations, and all structural congenital anomalies, regardless of gestational week, were recorded. A total of 247 831 singleton live births delivered at gestational ages of 20–42 weeks to women from northern and southern China with full information on FA intake were included. Limb reduction defects were classified by subtype and maternal FA supplementation. Results The prevalence of limb reduction defects was 2.7 per 10 000 births among women who took FA compared with 9.7 per 10 000 births among those who did not take FA in northern China; the prevalence was 4.5 and 3.8 per 10 000 births, respectively, in southern China. In both unadjusted and adjusted analyses, the estimated relative risk for upper limb reduction defects [odds ratio (OR) = 0.17, 95% confidence interval (CI): 0.04, 0.63] and total limb reduction defects (OR = 0.24, 95% CI: 0.08, 0.70) in northern China, but not for lower limb reduction defects ,was significantly decreased in association with FA supplementation in northern China. There was no association between FA supplementation and either an increased or decreased risk for limb reduction defects in southern China. Conclusions FA supplementation successfully reduces the prevalence of limb reduction defects in northern China, whose population has low folate concentrations.


2012 ◽  
Vol 83 (4) ◽  
pp. 220-230 ◽  
Author(s):  
Filemon Dela Cruz ◽  
Melissa Terry ◽  
Igor Matushansky

1996 ◽  
Vol 155 (6) ◽  
pp. 483-490 ◽  
Author(s):  
Julia Métneki ◽  
Andrew E. Czeizel ◽  
Jane A. Evans

PEDIATRICS ◽  
1991 ◽  
Vol 87 (3) ◽  
pp. 417-418
Author(s):  
H. EUGENE HOYME

In Reply.— Dr Bays has pointed out that congenital limb reduction defects associated with prenatal exposure to cocaine may be quite common. I would agree that such limb and digital disruptions are occasional accompaniments of fetal exposure to maternal cocaine abuse. However, the exact magnitude of individual fetal risk for prenatal vascular disruption associated with such exposure remains to be delineated. One must take the percentage of cocaine-exposed children in this report as the minimal number of exposed because many of the medical records did not record prenatal drug exposure.


PEDIATRICS ◽  
1990 ◽  
Vol 85 (5) ◽  
pp. 743-747
Author(s):  
H. Eugene Hoyme ◽  
Kenneth Lyons Jones ◽  
Suzanne D. Dixon ◽  
Tamison Jewett ◽  
James W. Hanson ◽  
...  

The question of the potential teratogenicity of cocaine has been raised by the increasing frequency of its abuse in the United States. In previous studies, an increased incidence has been documented of spontaneous abortion, placental abruption, prematurity, intrauterine growth retardation, and neurologic deficits in the infants of women who abused cocaine. More recently, it has been suggested in studies that fetal vascular disruption accompanying maternal cocaine abuse may lead to cavitary central nervous system lesions and genitourinary anomalies. In this article, 10 children born of women who abused cocaine are described, 9 of whom have congenital limb reduction defects and/or intestinal atresia or infarction. The spectrum of anomalies associated with embryonic and fetal vascular disruption accompanying maternal cocaine abuse is thus enlarged. The specific risk for congenital anomalies accompanying maternal cocaine abuse during an individual pregnancy is unknown. However, data from these patients and the available literature suggest that counseling pregnant women concerning cocaine use should incorporate warnings about the possibility of associated embryonic or fetal vascular disruption.


1986 ◽  
Vol 155 (5) ◽  
pp. 1072-1078 ◽  
Author(s):  
Anne Kricker ◽  
Jane W. Elliott ◽  
Jill M. Forrest ◽  
Janet McCredie

The Lancet ◽  
1975 ◽  
Vol 305 (7912) ◽  
pp. 931 ◽  
Author(s):  
D.T. Janerich ◽  
J.M. Piper ◽  
D.M. Glebatis

Sign in / Sign up

Export Citation Format

Share Document